Report cover image

Global Anti-VEGF Therapy for Cancer Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 192 Pages
SKU # APRC20282846

Description

Summary

According to APO Research, The global Anti-VEGF Therapy for Cancer market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Anti-VEGF Therapy for Cancer is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Anti-VEGF Therapy for Cancer is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Anti-VEGF Therapy for Cancer is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Anti-VEGF Therapy for Cancer is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Anti-VEGF Therapy for Cancer include Chia Tai Tianqing, Jiangsu Hengrui Pharmaceuticals, Sanofi, Roche, Pfizer, Novartis, Janssen Biotech, Exelixis and Eli Lilly, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes


This report presents an overview of global market for Anti-VEGF Therapy for Cancer, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Anti-VEGF Therapy for Cancer, also provides the revenue of main regions and countries. Of the upcoming market potential for Anti-VEGF Therapy for Cancer, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Anti-VEGF Therapy for Cancer revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Anti-VEGF Therapy for Cancer market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Anti-VEGF Therapy for Cancer revenue, projected growth trends, production technology, application and end-user industry.

Anti-VEGF Therapy for Cancer Segment by Company

Chia Tai Tianqing
Jiangsu Hengrui Pharmaceuticals
Sanofi
Roche
Pfizer
Novartis
Janssen Biotech
Exelixis
Eli Lilly
Eisai
Boehringer Ingelheim
Bayer
AstraZeneca
Anti-VEGF Therapy for Cancer Segment by Type

VEGF Inhibitors
VEGFR Inhibitors
Anti-VEGF Therapy for Cancer Segment by Application

Non-small Cell Lung Cancer
Cervical Cancer
Colorectal Cancer
Renal Cell Carcinoma
Medullary Thyroid Cancer
Other
Anti-VEGF Therapy for Cancer Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-VEGF Therapy for Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-VEGF Therapy for Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-VEGF Therapy for Cancer.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Anti-VEGF Therapy for Cancer in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Anti-VEGF Therapy for Cancer company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anti-VEGF Therapy for Cancer revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

192 Pages
1 Market Overview
1.1 Product Definition
1.2 Anti-VEGF Therapy for Cancer Market by Type
1.2.1 Global Anti-VEGF Therapy for Cancer Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 VEGF Inhibitors
1.2.3 VEGFR Inhibitors
1.3 Anti-VEGF Therapy for Cancer Market by Application
1.3.1 Global Anti-VEGF Therapy for Cancer Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Non-small Cell Lung Cancer
1.3.3 Cervical Cancer
1.3.4 Colorectal Cancer
1.3.5 Renal Cell Carcinoma
1.3.6 Medullary Thyroid Cancer
1.3.7 Other
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Anti-VEGF Therapy for Cancer Market Dynamics
2.1 Anti-VEGF Therapy for Cancer Industry Trends
2.2 Anti-VEGF Therapy for Cancer Industry Drivers
2.3 Anti-VEGF Therapy for Cancer Industry Opportunities and Challenges
2.4 Anti-VEGF Therapy for Cancer Industry Restraints
3 Global Growth Perspective
3.1 Global Anti-VEGF Therapy for Cancer Market Perspective (2020-2031)
3.2 Global Anti-VEGF Therapy for Cancer Growth Trends by Region
3.2.1 Global Anti-VEGF Therapy for Cancer Market Size by Region: 2020 VS 2024 VS 2031
3.2.2 Global Anti-VEGF Therapy for Cancer Market Size by Region (2020-2025)
3.2.3 Global Anti-VEGF Therapy for Cancer Market Size by Region (2026-2031)
4 Competitive Landscape by Players
4.1 Global Anti-VEGF Therapy for Cancer Revenue by Players
4.1.1 Global Anti-VEGF Therapy for Cancer Revenue by Players (2020-2025)
4.1.2 Global Anti-VEGF Therapy for Cancer Revenue Market Share by Players (2020-2025)
4.1.3 Global Anti-VEGF Therapy for Cancer Players Revenue Share Top 10 and Top 5 in 2024
4.2 Global Anti-VEGF Therapy for Cancer Key Players Ranking, 2023 VS 2024 VS 2025
4.3 Global Anti-VEGF Therapy for Cancer Key Players Headquarters & Area Served
4.4 Global Anti-VEGF Therapy for Cancer Players, Product Type & Application
4.5 Global Anti-VEGF Therapy for Cancer Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global Anti-VEGF Therapy for Cancer Market CR5 and HHI
4.6.3 2024 Anti-VEGF Therapy for Cancer Tier 1, Tier 2, and Tier 3
5 Anti-VEGF Therapy for Cancer Market Size by Type
5.1 Global Anti-VEGF Therapy for Cancer Revenue by Type (2020 VS 2024 VS 2031)
5.2 Global Anti-VEGF Therapy for Cancer Revenue by Type (2020-2031)
5.3 Global Anti-VEGF Therapy for Cancer Revenue Market Share by Type (2020-2031)
6 Anti-VEGF Therapy for Cancer Market Size by Application
6.1 Global Anti-VEGF Therapy for Cancer Revenue by Application (2020 VS 2024 VS 2031)
6.2 Global Anti-VEGF Therapy for Cancer Revenue by Application (2020-2031)
6.3 Global Anti-VEGF Therapy for Cancer Revenue Market Share by Application (2020-2031)
7 Company Profiles
7.1 Chia Tai Tianqing
7.1.1 Chia Tai Tianqing Comapny Information
7.1.2 Chia Tai Tianqing Business Overview
7.1.3 Chia Tai Tianqing Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2020-2025)
7.1.4 Chia Tai Tianqing Anti-VEGF Therapy for Cancer Product Portfolio
7.1.5 Chia Tai Tianqing Recent Developments
7.2 Jiangsu Hengrui Pharmaceuticals
7.2.1 Jiangsu Hengrui Pharmaceuticals Comapny Information
7.2.2 Jiangsu Hengrui Pharmaceuticals Business Overview
7.2.3 Jiangsu Hengrui Pharmaceuticals Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2020-2025)
7.2.4 Jiangsu Hengrui Pharmaceuticals Anti-VEGF Therapy for Cancer Product Portfolio
7.2.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
7.3 Sanofi
7.3.1 Sanofi Comapny Information
7.3.2 Sanofi Business Overview
7.3.3 Sanofi Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2020-2025)
7.3.4 Sanofi Anti-VEGF Therapy for Cancer Product Portfolio
7.3.5 Sanofi Recent Developments
7.4 Roche
7.4.1 Roche Comapny Information
7.4.2 Roche Business Overview
7.4.3 Roche Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2020-2025)
7.4.4 Roche Anti-VEGF Therapy for Cancer Product Portfolio
7.4.5 Roche Recent Developments
7.5 Pfizer
7.5.1 Pfizer Comapny Information
7.5.2 Pfizer Business Overview
7.5.3 Pfizer Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2020-2025)
7.5.4 Pfizer Anti-VEGF Therapy for Cancer Product Portfolio
7.5.5 Pfizer Recent Developments
7.6 Novartis
7.6.1 Novartis Comapny Information
7.6.2 Novartis Business Overview
7.6.3 Novartis Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2020-2025)
7.6.4 Novartis Anti-VEGF Therapy for Cancer Product Portfolio
7.6.5 Novartis Recent Developments
7.7 Janssen Biotech
7.7.1 Janssen Biotech Comapny Information
7.7.2 Janssen Biotech Business Overview
7.7.3 Janssen Biotech Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2020-2025)
7.7.4 Janssen Biotech Anti-VEGF Therapy for Cancer Product Portfolio
7.7.5 Janssen Biotech Recent Developments
7.8 Exelixis
7.8.1 Exelixis Comapny Information
7.8.2 Exelixis Business Overview
7.8.3 Exelixis Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2020-2025)
7.8.4 Exelixis Anti-VEGF Therapy for Cancer Product Portfolio
7.8.5 Exelixis Recent Developments
7.9 Eli Lilly
7.9.1 Eli Lilly Comapny Information
7.9.2 Eli Lilly Business Overview
7.9.3 Eli Lilly Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2020-2025)
7.9.4 Eli Lilly Anti-VEGF Therapy for Cancer Product Portfolio
7.9.5 Eli Lilly Recent Developments
7.10 Eisai
7.10.1 Eisai Comapny Information
7.10.2 Eisai Business Overview
7.10.3 Eisai Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2020-2025)
7.10.4 Eisai Anti-VEGF Therapy for Cancer Product Portfolio
7.10.5 Eisai Recent Developments
7.11 Boehringer Ingelheim
7.11.1 Boehringer Ingelheim Comapny Information
7.11.2 Boehringer Ingelheim Business Overview
7.11.3 Boehringer Ingelheim Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2020-2025)
7.11.4 Boehringer Ingelheim Anti-VEGF Therapy for Cancer Product Portfolio
7.11.5 Boehringer Ingelheim Recent Developments
7.12 Bayer
7.12.1 Bayer Comapny Information
7.12.2 Bayer Business Overview
7.12.3 Bayer Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2020-2025)
7.12.4 Bayer Anti-VEGF Therapy for Cancer Product Portfolio
7.12.5 Bayer Recent Developments
7.13 AstraZeneca
7.13.1 AstraZeneca Comapny Information
7.13.2 AstraZeneca Business Overview
7.13.3 AstraZeneca Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2020-2025)
7.13.4 AstraZeneca Anti-VEGF Therapy for Cancer Product Portfolio
7.13.5 AstraZeneca Recent Developments
8 North America
8.1 North America Anti-VEGF Therapy for Cancer Revenue (2020-2031)
8.2 North America Anti-VEGF Therapy for Cancer Revenue by Type (2020-2031)
8.2.1 North America Anti-VEGF Therapy for Cancer Revenue by Type (2020-2025)
8.2.2 North America Anti-VEGF Therapy for Cancer Revenue by Type (2026-2031)
8.3 North America Anti-VEGF Therapy for Cancer Revenue Share by Type (2020-2031)
8.4 North America Anti-VEGF Therapy for Cancer Revenue by Application (2020-2031)
8.4.1 North America Anti-VEGF Therapy for Cancer Revenue by Application (2020-2025)
8.4.2 North America Anti-VEGF Therapy for Cancer Revenue by Application (2026-2031)
8.5 North America Anti-VEGF Therapy for Cancer Revenue Share by Application (2020-2031)
8.6 North America Anti-VEGF Therapy for Cancer Revenue by Country
8.6.1 North America Anti-VEGF Therapy for Cancer Revenue by Country (2020 VS 2024 VS 2031)
8.6.2 North America Anti-VEGF Therapy for Cancer Revenue by Country (2020-2025)
8.6.3 North America Anti-VEGF Therapy for Cancer Revenue by Country (2026-2031)
8.6.4 United States
8.6.5 Canada
8.6.6 Mexico
9 Europe
9.1 Europe Anti-VEGF Therapy for Cancer Revenue (2020-2031)
9.2 Europe Anti-VEGF Therapy for Cancer Revenue by Type (2020-2031)
9.2.1 Europe Anti-VEGF Therapy for Cancer Revenue by Type (2020-2025)
9.2.2 Europe Anti-VEGF Therapy for Cancer Revenue by Type (2026-2031)
9.3 Europe Anti-VEGF Therapy for Cancer Revenue Share by Type (2020-2031)
9.4 Europe Anti-VEGF Therapy for Cancer Revenue by Application (2020-2031)
9.4.1 Europe Anti-VEGF Therapy for Cancer Revenue by Application (2020-2025)
9.4.2 Europe Anti-VEGF Therapy for Cancer Revenue by Application (2026-2031)
9.5 Europe Anti-VEGF Therapy for Cancer Revenue Share by Application (2020-2031)
9.6 Europe Anti-VEGF Therapy for Cancer Revenue by Country
9.6.1 Europe Anti-VEGF Therapy for Cancer Revenue by Country (2020 VS 2024 VS 2031)
9.6.2 Europe Anti-VEGF Therapy for Cancer Revenue by Country (2020-2025)
9.6.3 Europe Anti-VEGF Therapy for Cancer Revenue by Country (2026-2031)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
9.6.9 Spain
9.6.10 Netherlands
9.6.11 Switzerland
9.6.12 Sweden
9.6.13 Poland
10 China
10.1 China Anti-VEGF Therapy for Cancer Revenue (2020-2031)
10.2 China Anti-VEGF Therapy for Cancer Revenue by Type (2020-2031)
10.2.1 China Anti-VEGF Therapy for Cancer Revenue by Type (2020-2025)
10.2.2 China Anti-VEGF Therapy for Cancer Revenue by Type (2026-2031)
10.3 China Anti-VEGF Therapy for Cancer Revenue Share by Type (2020-2031)
10.4 China Anti-VEGF Therapy for Cancer Revenue by Application (2020-2031)
10.4.1 China Anti-VEGF Therapy for Cancer Revenue by Application (2020-2025)
10.4.2 China Anti-VEGF Therapy for Cancer Revenue by Application (2026-2031)
10.5 China Anti-VEGF Therapy for Cancer Revenue Share by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Anti-VEGF Therapy for Cancer Revenue (2020-2031)
11.2 Asia Anti-VEGF Therapy for Cancer Revenue by Type (2020-2031)
11.2.1 Asia Anti-VEGF Therapy for Cancer Revenue by Type (2020-2025)
11.2.2 Asia Anti-VEGF Therapy for Cancer Revenue by Type (2026-2031)
11.3 Asia Anti-VEGF Therapy for Cancer Revenue Share by Type (2020-2031)
11.4 Asia Anti-VEGF Therapy for Cancer Revenue by Application (2020-2031)
11.4.1 Asia Anti-VEGF Therapy for Cancer Revenue by Application (2020-2025)
11.4.2 Asia Anti-VEGF Therapy for Cancer Revenue by Application (2026-2031)
11.5 Asia Anti-VEGF Therapy for Cancer Revenue Share by Application (2020-2031)
11.6 Asia Anti-VEGF Therapy for Cancer Revenue by Country
11.6.1 Asia Anti-VEGF Therapy for Cancer Revenue by Country (2020 VS 2024 VS 2031)
11.6.2 Asia Anti-VEGF Therapy for Cancer Revenue by Country (2020-2025)
11.6.3 Asia Anti-VEGF Therapy for Cancer Revenue by Country (2026-2031)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Anti-VEGF Therapy for Cancer Revenue (2020-2031)
12.2 SAMEA Anti-VEGF Therapy for Cancer Revenue by Type (2020-2031)
12.2.1 SAMEA Anti-VEGF Therapy for Cancer Revenue by Type (2020-2025)
12.2.2 SAMEA Anti-VEGF Therapy for Cancer Revenue by Type (2026-2031)
12.3 SAMEA Anti-VEGF Therapy for Cancer Revenue Share by Type (2020-2031)
12.4 SAMEA Anti-VEGF Therapy for Cancer Revenue by Application (2020-2031)
12.4.1 SAMEA Anti-VEGF Therapy for Cancer Revenue by Application (2020-2025)
12.4.2 SAMEA Anti-VEGF Therapy for Cancer Revenue by Application (2026-2031)
12.5 SAMEA Anti-VEGF Therapy for Cancer Revenue Share by Application (2020-2031)
12.6 SAMEA Anti-VEGF Therapy for Cancer Revenue by Country
12.6.1 SAMEA Anti-VEGF Therapy for Cancer Revenue by Country (2020 VS 2024 VS 2031)
12.6.2 SAMEA Anti-VEGF Therapy for Cancer Revenue by Country (2020-2025)
12.6.3 SAMEA Anti-VEGF Therapy for Cancer Revenue by Country (2026-2031)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.